Bill Hunter

Dr. Bill Hunter was appointed Chairman of Tensive S.r.l. in August 2025, a clinical-stage advanced biomaterials company developing bioresorbable scaffolds for breast reconstruction following lumpectomy. He brings more than 30 years of leadership in the medical technology and life sciences sectors and is based in Vancouver, British Columbia.

Hunter is founder, president, CEO and CMO of Canary Medical, a medical data company developing implantable sensor technology. He holds a Doctorate of Medicine from the University of British Columbia, a Master of Science from the University of British Columbia, and a Bachelor of Science from McGill University. He is an innovator with over 200 patents and patent applications, including pioneering cardiovascular and wound closure devices.

Most recently, Hunter was CEO of Correvio (CORV:NASDAQ), where he oversaw development of its direct sales force in Europe, acquisition of a complementary product line (AGGRASTAT), assembly of an international distribution network, and increased company valuation over five-fold. Prior to that, he was Founder/CEO of Angiotech (ANPI:NASDAQ), a world leader in drug-loaded medical devices that achieved a market capitalization exceeding $2 billion. He has overseen development of products used in over 50 million patients, generating revenues exceeding $25 billion.

Career history

• Founder, President, CEO and CMO, Canary Medical
• President and CEO, Correvio Pharma Corp. (2007–2019)
• Founder and CEO, Angiotech Pharmaceuticals
• Director at multiple medical device and pharmaceutical companies

What Bill Hunter could bring to Tensive: Hunter's proven track record guiding breakthrough medical device technologies from concept through regulatory approval and commercialization positions him to accelerate Tensive's REGENERA and SOFTAG bioresorbable scaffolds toward market approval in Europe and the United States. His extensive experience building international sales and distribution networks, combined with his innovation portfolio in implantable device platforms, directly aligns with Tensive's objectives to transition from clinical-stage development into commercial operations during a pivotal phase of regulatory advancement.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.